{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-258366","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2026-06-05T11:05:17+00:00","discovered_at":"2026-06-05T11:10:00.265414+00:00","generated_at":"2026-06-05T11:10:56.458343+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Seres receives $25M milestone buyout from Nestlé; restructures lease to cut costs, extends cash runway into Q1 2027","bullets":["Nestlé Health Science pays $25M in two $12.5M installments (July & Oct 2026) to buy out future VOWST sales milestones.","Lease amendment reduces space from 82,714 to 36,882 sq ft, cuts annual rent to $79.70/sq ft, extends term to Dec 2036.","Lease restructuring reduces ongoing annual facility cash costs; includes $4.5M termination fee, $5.2M deferred payment, and landlord draws $6.3M letter of credit.","Cash balance $29.8M as of Mar 31, 2026; projected operating cash runway extends well into Q1 2027.","Clinical data from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected later in June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-258366","json":"https://secwatch.observer/filing/0001193125-26-258366.json","markdown":"https://secwatch.observer/filing/0001193125-26-258366.md","text":"https://secwatch.observer/filing/0001193125-26-258366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526258366/0001193125-26-258366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526258366/d156701d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:10:56.458343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7bc8e4ef63d57cef999ffa570164e9b348baedc","claim":"Seres Therapeutics, Inc. amended Lease Amendment with 101 CPD LLC valued at approximately $33.9 million (effective 2026-06-04).","evidence_excerpt":"On June 4, 2026, the Company entered into the First Amendment to Lease (the “Lease Amendment”) with 101 CPD LLC (f/k/a HCP/King 101 CPD LLC), a Delaware limited liability company (the “Landlord”), which amends the Lease Agreement, dated September 22, 2021, by and between the Company and the Landlord (as amended, the “Lease”), pursuant to which the Company leases approximately 82,714 rentable square feet of office and laboratory space located at 101 CambridgePark Drive, Cambridge, Massachusetts (the “Existing Premises”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526258366/0001193125-26-258366-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"lease"},{"label":"Counterparty","value":"101 CPD LLC"},{"label":"Value","value":"approximately $33.9 million"},{"label":"Effective","value":"2026-06-04"}],"fact_type":"material_agreement"},{"claim_id":"ed2903e9fb73097ec72989b5dcd1f968db3b3861","claim":"Seres Therapeutics, Inc. amended APA Amendment with Société des Produits Nestlé S.A. valued at $25.0 million (effective 2026-06-02).","evidence_excerpt":"On June 2, 2026, Seres Therapeutics, Inc. (the “Company”) entered into Amendment No. 1 (the “APA Amendment”) to the Asset Purchase Agreement, dated as of August 5, 2024 (as previously amended by that certain Letter Agreement, dated September 30, 2024 and that certain Letter Agreement, dated December 31, 2024, the “Purchase Agreement”), by and between the Company and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“SPN”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526258366/0001193125-26-258366-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Société des Produits Nestlé S.A."},{"label":"Value","value":"$25.0 million"},{"label":"Effective","value":"2026-06-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}